From Wikipedia, the free encyclopedia
Jump to: navigation, search
Actelion Pharmaceuticals Ltd.
public company
Industry Pharmaceuticals/Biotech
Founded 1997
Founder Jean-Paul Clozel, Martine Clozel, Walter Fischli, André J. Müller and Thomas Widmann
Headquarters Gewerbestrasse 16, Allschwil, Basel country, Switzerland
Area served
Research and Development of medicines for unmet medical need
Key people
Jean-Paul Clozel, Chief Executive Office
Guy Braunstein, Global Clinical Development
Otto Schwarz, Chief Operating Officer
Nicholas Franco, Chief Business Officer
André C. Muller, Chief Financial Officer
Products Tracleer, Ventavis, Zavesca, Veletri, Opsumit
Revenue 1,929 mio CHF
457.3 mio CHF
390.6 mio CHF
Number of employees
2467 (January 2011)

Actelion is a pharmaceuticals and bio-technology company established in December 1997, headquartered in Allschwil near Basel in Switzerland.[2] Its CEO and co-founder is cardiologist Jean-Paul Clozel.[3]

Actelion specializes in orphan diseases.[4] Actelion scientists were among the first to work in the field of endothelian receptor antagonists.[5] The company name might be a reminder for its first product, an endothelian receptor antagonist and the verb "action", "act upon". Actelion was initially financed with venture capital provided through a syndicate including Atlas Venture, Sofinnova and HealthCap.

Actelion has 29 operative affiliates around the world, including the United States, Canada, Brazil, Australia, Japan, Switzerland and a number of EU countries. The Swiss affiliate is located in Baden, the German affiliate in Freiburg, the Austrian one in Vienna, the French one in Paris and the UK affiliate is located in London[6]

In 2006, the company established the Actelion Endothelin Research Award programme which supports selected clinical research projects.

In January 2017, Johnson & Johnson announced that it would purchase the company for $30 billion.[7] Actelion's research and development unit would also be spun off after the acquisition.[8]


Actelion currently has 10 compounds in its pipeline – including 3 in late-stage development – and 4 medicines on the market for orphan diseases:


Late-stage drugs in development by Actelion include:

Key figures[edit]

By January 2011, Actelion had a total of 2,467 employees, 392 in research, 640 in development and 1017 in sales and marketing. In 2010, Actelion's sales amounted to 1,929 million CHF.[14]

Actelion's shares have been listed on the SIX Swiss Exchange (ticker symbol ATLN) since 2000 SWX Swiss Exchange Swiss Leader Index. In September 2008, Actelion shares began trading as part of the Swiss Market Index.[2][15][16][17]


Actelion received the "Prix Hermès de l'innovation" (Hermès Award for Innovation) in April 2011:[18] The "European Institute for Creative Strategy and Innovation", the creator of the Prix Hermès, was founded in 2003 in France.

The "performance report for Swiss pharma websites" awarded Actelion the first Prize in the second consecutive year:.[19]

Notes and references[edit]

See also[edit]

External links[edit]